Pharma Bio Services(PBSV)
$0.480.00 (0.00%)
PBSV
Pharma Bio Services financials statements
$0.48
At close:0.00 (0.00%)
Want to see PBSV full AI Analyst Report?
Pharma Bio Services (PBSV) Ratios
47 Followers
Pharma Bio Services Ratios
PBSV's free cash flow for Q3 2026 was $60.89M. For the 2026 fiscal year, PBSV's free cash flow was decreased by $-1.39K and operating cash flow was $60.89M. See a summary of the company’s cash flow.
| Ratios | Oct 25 | Oct 24 | Oct 23 | Oct 22 | Jan 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.70 | 8.32 | 9.01 | 9.46 | 8.61 |
| Quick Ratio | 7.70 | 8.32 | 9.01 | 9.46 | 8.61 |
| Cash Ratio | 1.94 | 3.59 | 4.85 | 6.86 | 6.59 |
| Solvency Ratio | 0.07 | -0.23 | 0.40 | 0.26 | -0.40 |
| Operating Cash Flow Ratio | -0.12 | -0.30 | 0.88 | 0.28 | 0.30 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 11.65M | $ 13.12M | $ 15.63M | $ 15.85M | $ 17.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.02 | 0.02 | 0.03 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.02 | 0.03 | 0.03 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.02 | 0.03 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.19 | 1.23 | 1.25 | 1.26 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.01 | 0.02 | 0.02 | 0.03 |
| Net Debt to EBITDA | -24.85 | 5.94 | -7.70 | -11.40 | 4.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 32.33% | 26.46% | 29.84% | 25.16% | 26.65% |
| EBIT Margin | -1.05% | -13.54% | 6.58% | 6.06% | -19.16% |
| EBITDA Margin | 1.50% | -11.64% | 7.73% | 6.32% | -18.80% |
| Operating Profit Margin | -7.08% | -13.54% | 6.58% | 6.06% | -19.16% |
| Pretax Profit Margin | -1.05% | -7.94% | 9.94% | 6.13% | -9.33% |
| Net Profit Margin | -1.12% | -8.18% | 7.72% | 5.19% | -10.39% |
| Continuous Operations Profit Margin | -1.12% | -8.18% | 7.72% | 5.19% | -10.39% |
| Net Income Per EBT | 106.58% | 102.93% | 77.64% | 84.71% | 111.37% |
| EBT Per EBIT | 14.78% | 58.67% | 151.02% | 101.14% | 48.68% |
| Return on Assets (ROA) | -0.74% | -4.77% | 6.58% | 4.87% | -8.73% |
| Return on Equity (ROE) | -0.84% | -5.67% | 8.12% | 6.08% | -11.05% |
| Return on Capital Employed (ROCE) | -5.35% | -8.94% | 6.30% | 6.34% | -18.12% |
| Return on Invested Capital (ROIC) | -5.34% | -8.84% | 4.85% | 5.33% | -18.01% |
| Return on Tangible Assets | -0.74% | -4.77% | 6.58% | 4.87% | -8.73% |
| Earnings Yield | -0.81% | -5.84% | 6.71% | 5.09% | -8.56% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.81 | 3.79 | 4.31 | 3.89 | 4.36 |
| Payables Turnover | 6.15 | 6.20 | 8.12 | 8.91 | 7.06 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 61.89 | 25.85 | 43.61 | 33.66 | 26.98 |
| Asset Turnover | 0.66 | 0.58 | 0.85 | 0.94 | 0.84 |
| Working Capital Turnover Ratio | 0.71 | 0.61 | 0.97 | 1.02 | 0.89 |
| Cash Conversion Cycle | 36.33 | 37.52 | 39.76 | 52.78 | 32.03 |
| Days of Sales Outstanding | 95.73 | 96.38 | 84.73 | 93.75 | 83.71 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 59.39 | 58.86 | 44.97 | 40.97 | 51.68 |
| Operating Cycle | 95.73 | 96.38 | 84.73 | 93.75 | 83.71 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.02 | 0.08 | 0.03 | 0.03 |
| Free Cash Flow Per Share | -0.01 | -0.03 | 0.08 | 0.02 | 0.03 |
| Dividend Paid and CapEx Coverage Ratio | -0.12 | -0.30 | 1.09 | 0.17 | 0.46 |
| Capital Expenditure Coverage Ratio | -32.34 | -3.55 | 260.79 | 30.75 | 74.21 |
| Operating Cash Flow Coverage Ratio | -7.45 | -2.92 | 5.46 | 1.22 | 1.30 |
| Operating Cash Flow to Sales Ratio | -0.02 | -0.06 | 0.11 | 0.03 | 0.04 |
| Free Cash Flow Yield | -1.79% | -5.45% | 9.65% | 2.90% | 3.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -122.73 | -17.13 | 14.90 | 19.65 | -11.68 |
| Price-to-Sales (P/S) Ratio | 1.38 | 1.40 | 1.15 | 1.02 | 1.21 |
| Price-to-Book (P/B) Ratio | 1.04 | 0.97 | 1.21 | 1.19 | 1.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -55.94 | -18.34 | 10.36 | 34.51 | 30.74 |
| Price-to-Operating Cash Flow Ratio | -57.67 | -23.50 | 10.32 | 33.39 | 30.33 |
| Price-to-Earnings Growth (PEG) Ratio | 1.41 | 0.11 | 0.49 | -0.13 | 0.06 |
| Enterprise Value Multiple | 67.06 | -6.10 | 7.18 | 4.74 | -2.00 |
| Enterprise Value | 9.04M | 6.75M | 9.42M | 5.81M | 7.56M |
| EV to EBITDA | 67.06 | -6.10 | 7.18 | 4.74 | -2.00 |
| EV to Sales | 1.00 | 0.71 | 0.55 | 0.30 | 0.38 |
| EV to Free Cash Flow | -40.81 | -9.29 | 5.00 | 10.13 | 9.52 |
| EV to Operating Cash Flow | -42.07 | -11.91 | 4.98 | 9.80 | 9.39 |
| Tangible Book Value Per Share | 0.52 | 0.60 | 0.70 | 0.72 | 0.82 |
| Shareholders’ Equity Per Share | 0.52 | 0.60 | 0.70 | 0.72 | 0.82 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | -0.03 | 0.22 | 0.15 | -0.11 |
| Revenue Per Share | 0.39 | 0.41 | 0.74 | 0.84 | 0.87 |
| Net Income Per Share | -0.00 | -0.03 | 0.06 | 0.04 | -0.09 |
| Tax Burden | 1.07 | 1.03 | 0.78 | 0.85 | 1.11 |
| Interest Burden | 1.00 | 0.59 | 1.51 | 1.01 | 0.49 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.39 | 0.40 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.14 | 0.73 | 1.44 | 0.59 | -0.39 |
Currency in USD

